2. Academic Validation
  3. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

  • J Hematol Oncol. 2020 Jun 29;13(1):83. doi: 10.1186/s13045-020-00917-y.
Xing Huang 1 2 3,  Xiaozhen Zhang 4 5 6,  Enliang Li 4 5 6,  Gang Zhang 4 5 6,  Xun Wang 4 5 6,  Tianyu Tang 4 5 6,  Xueli Bai 7 8 9,  Tingbo Liang 10 11 12
Affiliations

Affiliations

  • 1 Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China. huangxing66@zju.edu.cn.
  • 2 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China. huangxing66@zju.edu.cn.
  • 3 Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310003, Zhejiang, China. huangxing66@zju.edu.cn.
  • 4 Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
  • 5 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
  • 6 Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310003, Zhejiang, China.
  • 7 Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.
  • 8 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.
  • 9 Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.
  • 10 Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China. liangtingbo@zju.edu.cn.
  • 11 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China. liangtingbo@zju.edu.cn.
  • 12 Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310003, Zhejiang, China. liangtingbo@zju.edu.cn.
PMID: 32600443 DOI: 10.1186/s13045-020-00917-y
Abstract

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on Cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in Cancer Immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.

Keywords

Cancer immunotherapy; Co-inhibition; Co-stimulation; Immune checkpoint; VISTA.

Figures
Products